出版社：American Society for Biochemistry and Molecular Biology
摘要：To determine if the dose of peptide administered or the plasma level was more important, doses of 0.15, 0.45, 4.5, or 45 mg/kg/day of the peptide D-4F were administered orally or subcutaneously (SQ) to apoliptotein (apo)E null mice. Plasma levels of peptide were ∼1,000-fold higher when administered SQ compared with orally. Regardless of the route of administration, doses of 4.5 and 45 mg/kg significantly reduced plasma serum amyloid A (SAA) levels and the HDL inflammatory index ( P P P P i ) the dose of 4F administered and not the plasma level achieved determines efficacy; ii ) the intestine may be a major site of action for the peptide regardless of the route of administration.
